Target based drug discovery

However, the target validation step is unique to target-based drug discovery. 

Central tendency, 226-227 Chemical genomics, 178 Chemical tools, in target-based drug discovery, 178-179 Chemokine C receptor type 1, 133 Chemokine receptors, 6, 44, 53, 129, 132, 177... 

Tang Herbal, 147 Target-based drug discovery biological targets, 180-184 chemical end point in, 180 chemical tools, 178-179 definition of, 5 description of, 175-177 linear approach, 176 orphan receptors, 180 preclinical process in, 176-177 random variation in gene expression, 178... 

Deng, G., Sanyal, G. Applications of mass spectrometry in early stages of target based drug discovery. / Pharm Biomed Anal 2006, 40, 528—538. 

Target-Based Drug Discovery or Finding Clinical Candidates... 

Sams-Dodd, F. Target-based drug discovery is something wrong . Drug Discov. Today, 2005, 10, 139-147. 

This raises the key test of target validation. Does a compound that has the appropriate potency, selectivity, and ADME properties, that is active in "predictive" animal models, and is free of other systems toxicology work in the targeted human disease state This is the ultimate test of a target-based drug discovery program. With the considerable compound attrition rates in moving from animals to diseased humans, this has not proven to be a predictable transition. A case in point is that of the NKl receptor activated by the peptide, substance P. 

---